Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4253446 | 0.71 | SMN1; SMN2 (0.53) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL5599082 | 0.69 | SMN1; SMN2 (0.46) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL19102433 | 0.67 | SMN1; SMN2 (0.44) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL20170045 | 0.65 | SMN1; SMN2 (0.43) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL5599103 | 0.65 | KMT2A (0.49) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL11134639 | 0.62 | SMN1; SMN2 (0.41) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL15329364 | 0.62 | SMN1; SMN2 (0.41) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL14564596 | 0.61 | SMN1; SMN2 (0.40) | SMN1; SMN2GLAKMT2AL3MBTL1 | |
| SCHEMBL7699680 | 0.59 | MAPT (0.40) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL12498446 | 0.59 | P2RX7 (0.42) | SMN1; SMN2GLAKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-11-16 | — | — | US | disclosed |
| EP-4110459-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-2697198-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2014-02-19 | — | — | EP | disclosed |
| EP-2681216-A2 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| WO-2012142513-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012118812-A2 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2012-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | RBM17, HNRNPA1, HNRNPAB | SMN1; SMN2 317/4885GLA 2971/4885KMT2A 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.